microRNA在乳腺癌耐药中的作用

乳腺癌是危害全球女性健康的主要疾病,而乳腺癌患者对现有治疗方法产生获得性耐药成为目前乳腺癌临床治疗所面临的难题.微小RNA (miRNA)是一种内源性的非编码RNA,它参与调控多种生物学过程,包括细胞增殖、侵袭、转移、上皮间质转化和耐药等.获得性耐药包含多种复杂机制,可通过特定miRNA的异常表达影响细胞相关蛋白的表达、抗肿瘤药物与相应靶点的结合以及凋亡相关途径引起乳腺癌耐药.本文将重点关注在乳腺癌内分泌治疗、化疗、分子靶向治疗发生获得性耐药中表达异常的miRNA.相信miRNA能够成为乳腺癌临床诊断与治疗以及对抗获得性耐药的生物标志物和新的治疗靶点.

The role of microRNA in drug resistance of breast cancer

Breast cancer is a major disease which threatens the health of women around the world.Breast cancer patients have acquired resistance to existing treatment methods become the current clinical problems.MicroRNA(miRNA) is an endogenous non-coding RNA that participates in the regulation of a variety of biological processes,including cell proliferation,invasion,metastasis,epithelial interstitial transformation and drug resistance.Acquired resistance includes a variety of complex mechanisms that can affect the expression of cell-associated proteins through the abnormal expression of specific microRNAs,the binding of antineoplastic agents to the corresponding target,and the pathways associated with apoptosis.This article will focus on the expression of abnormal microRNA in acquired drug resistance which was caused by endocrine therapy,chemotherapy and molecular targeted therapy of breast cancer.miRNAs are considered as promising biomarkers and targets for diagnosis,treatments for acquired drug resistance of breast cancer.